Distinct disorders affecting the brain share common genetic origins

R Frank Kooy

Address: Department of Medical Genetics, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium

Email: frank.kooy@ua.ac.be

F1000 Biology Reports 2010, **2**:11 (doi:10.3410/B2-11)

The electronic version of this article is the complete one and can be found at: <http://f1000.com/reports/biology/content/2/11>

Abstract

Over the last few years, large cohorts of patients with distinct brain disorders of neuropsychiatric and neurological origin have been analyzed for copy number variation. Surprisingly, the same genetic abnormalities were found in cohorts of patients affected with mental retardation, autism, or schizophrenia.

Introduction and context

Copy number variation in brain disease

According to recent estimates, 5-12% of our genome is in a non-diploid state [1-3]. Copy number variation (CNV) discovery was enabled by the development of array-based techniques that detect chromosomal abnormalities at a resolution that may exceed that of traditional karyotyping under a light microscope by orders of magnitude. Initially, bacterial artificial chromosome arrays were used with a resolution in the megabase range but these were gradually replaced by oligonucleotide arrays with a resolution in the 10- to 100-kilobase range, thus enabling the detection of detailed CNV maps of the human genome. Broadly speaking, CNVs fall into two categories: the common ones that occur in a significant proportion of the general population and the rare ones that have been detected at a much lower frequency. The common CNVs are generally assumed to play an important role in the natural variation between individuals, including disease susceptibility, whereas the rare ones may cause disease.

It is well established that CNVs are responsible for at least 10% of all cases of mental retardation [4], predominantly defined by an intelligence quotient of two standard deviations below the mean. Many of the rare CNVs identified are unique and have been reported only once. Whether these are pathogenic depends on a

number of factors, including *de novo* occurrence, size of the deletion, and gene content. In contrast, recurrent CNVs are found in multiple unrelated patients, usually with common clinical manifestations [5]. Recurrent CNVs are mostly flanked by low copy repeats (LCRs), referred to as segmental duplications (Figure 1).

Over the past two years, cohorts of patients with disorders distinct from mental retardation were analyzed for CNV. Surprisingly, CNVs at specific chromosomal regions that are involved in mental retardation, including 1q21.1, 15q11-13, 16p11.2, 17p12, and 22q11.2, also appeared to be associated with autism (qualitative impairments in social interaction and communication) and schizophrenia (a psychotic disorder involving impairments in the perception of reality) (Figure 2). Moreover, the chromosomal regions encompassing the neurexin 1 (*NRXN1*) and the contactin-associated protein-like 2 (*CNTNAP2*) genes are also implicated in the three named disorders.

Major recent advances

Copy number variation discovery in autism and schizophrenia

Deletions of the chromosomal region 1q21.1, between two breakpoints (bps) defined as 3 and 4, were initially described with a wide range of pediatric phenotypes, including mild to moderate mental delay and dysmorphic

Figure 1. Non-allelic homologous recombination

Schematic representation of the non-allelic homologous recombination process, generating deletions as well as their reciprocal duplications by unequal alignment of homologous chromosomes. LCR, low copy repeat.

Figure 2. Schematic overview of genetic overlaps between mental retardation, autism spectrum disorders, and schizophrenia

Copy number variations that cause mental retardation disorders overlap, to some extent, with those that cause autistic spectrum disorders and even with a few that cause schizophrenia. CNTNAP2, contactin-associated protein-like 2.

features, microcephaly, cardiac abnormalities, and cataract [6]. The reciprocal microduplication was found predominantly in patients who presented with autism or autistic features [6,7]. At the same time, 1q21.1

bp3-bp4 microdeletions were identified in 0.25% of patients with schizophrenia but in only 0.02% of controls [8-11].

The chromosomal 15q11-13 region has a complex molecular architecture containing five LCR sequences or breakpoints, and in addition this chromosomal region is subject to genomic imprinting. Paternal deletions of the region between bp2 and bp3 result in Prader-Willi syndrome whereas maternal deletions of the same region result in Angelman syndrome [12]. Patients with an extended bp1-bp3 deletion present with a more severe form of the disorder and more commonly display autistic features. Maternal duplications of the bp2-bp3 region cause a clinically variable neurodevelopmental disorder frequently associated with autism [13]. In fact, this duplication, found in 1-3% of patients, is the leading known cause of this disorder. Deletions and occasionally duplications of the 15q13.3 bp4-bp5 region were found in patients with a highly variable degree of mental handicap, frequently including autistic features [14-16]. The same bp4-bp5 deletion was also one of the more frequently observed CNVs associated with schizophrenia [9]. The intermediate bp3-bp4 region seems of little clinical significance.

A 16p11.2 deletion was found initially in monozygotic twins with mild mental retardation and multiple congenital anomalies [17]. Subsequently, a strong association between the same microdeletion as well as the reciprocal microduplication and autism was reported [18-21]. The microdeletion is also found occasionally in controls, but with a 100-fold lower frequency. In addition, the microdeletion/duplication is a risk factor for schizophrenia [8,10].

But the abovementioned CNVs are not the only abnormalities associated with mental retardation, autism, and schizophrenia. A duplication of chromosome 17p12 is generally associated with Charcot-Marie-Tooth disease type 1A (CMT1A) but is also occasionally found in mentally handicapped or autistic populations [7,22]. A deletion of the same chromosomal region increases the risk for schizophrenia by a factor of 10 [23]. One of the most frequent microdeletion syndromes, the 22q11.2 deletion, is associated with developmental delay in nearly 50% of patients. However, the same deletion is also found in autistic patients as well as in schizophrenic patients [8,11,24]. The phenotype of the reciprocal duplication is highly variable [25]. In addition, rearrangements involving the *NRXN1* gene on chromosome 2p16 and the *CNTNAP2* gene on chromosome 7q35 have been found in patients with mental retardation, autism, or schizophrenia [7,8,10,26-31]. Both genes are members of the larger neurexin superfamily involved in cell-cell interactions in the nervous system [32]. In contrast to the CNVs mentioned above, the deletions in these cases were highly variable in size.

Future directions

Unexplained clinical heterogeneity

Thus, several CNVs appear to cause a series of clinically heterogeneous brain disorders, including mental retardation, autism, and schizophrenia. Penetrance of these CNVs may vary and in some cases the abnormalities are inherited from seemingly unaffected carriers. Such inherited CNVs are better seen as risk factors than as a causative factor *per se*. For instance, penetrance of the 16p11.2 duplication in schizophrenia is estimated to be 30-50%. In other words, carriers of this microduplication have an 8- to 24-fold increased risk of becoming affected [33], in range with that of other genomic aberrations taking away one copy of 1q21.1, 15q13 bp4-bp5, or *NRXN1* [8,9,34]. While this overview focuses on mental retardation, autism, and schizophrenia, it has to be mentioned that many of the CNVs discussed above have also been associated with a broad range of additional phenotypes, most notably attention deficit hyperactivity disorder, epilepsy, and different psychiatric disorders, including bipolar and major depressive disorder. Interestingly, both the 16p11.2 microdeletion and the 1q21.1 microduplication are associated with a combination of autism and relative macrocephaly. An increased head circumference in infancy has been reported in patients with autism [35], suggesting a possible relationship between neurodevelopmental disorders and brain volume.

Interpretation of the clinical heterogeneity requires a greater understanding of how the CNVs lead to disease. For the most part, the disease resulting from a CNV is

presumably due to an underexpression or overexpression of the genes in the deleted or duplicated region, respectively. In addition, it is possible that the deletion unmasks a recessive mutation on the other allele. However, imprinting, gene interruption, gene fusion, position, and transvection effects may also play a role in determining clinical heterogeneity and disease penetrance. In addition, it is possible that environmental variation of any kind influences the phenotype, but additional genetic factors could also play a role. The human genome is highly variant in both CNV content and single-nucleotide polymorphisms. Otherwise neutral genetic differences between individuals, in combination with the above-mentioned CNVs, might determine whether the patient presents with mental retardation, autism, or schizophrenia. The only known example of such modifying genetic alterations at present is a recurrent 16p12.1 microdeletion that modifies neurobehavioral phenotypes [36]. The presence of this microdeletion in addition to a second pathogenic CNV manifests clinically as mental retardation. Perhaps the analysis of new cohorts with an even larger number of samples might help us to identify additional modifiers unknown as of yet. Alternatively, studying the CNV in animal models with a much more controllable genetic background seems attractive [37]. Thus, although some of the genetic origins of neurodevelopmental disorders are now beginning to be understood, many discoveries need to be made before we will begin to understand the common pathways leading to each of these disorders.

Abbreviations

bp, breakpoint; *CNTNAP2*, contactin-associated protein-like 2; CNV, copy number variation; LCR, low copy repeat; *NRXN1*, neurexin 1.

Competing interests

The author declares that he has no competing interests.

Acknowledgments

The author thanks Denise Kerstens for help with the figures.

References

1. Zhang F, Gu W, Hurles ME, Lupski JR: **Copy number variation in human health, disease, and evolution.** *Annu Rev Genomics Hum Genet* 2009, **10**:451-81.
2. Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, Månér S, Massa H, Walker M, Chi M, Navin N, Lucito R, Healy J, Hicks J, Ye K, Reiner A, Gilliam TC, Trask B, Patterson N, Zetterberg A, Wigler M: **Large-scale copy number polymorphism in the human genome.** *Science* 2004, **305**:525-8.

F1000 Factor 8.5 Exceptional

Evaluated by Andrew Wilkie 16 Aug 2004, Michael O'Donovan 22 Sep 2004, Stephen Scherer 23 Sep 2004, Andrey Rzhetsky 24 Sep 2004, Niklas Dahl 04 Oct 2004, Andrew Belmont 14 Oct 2004

3. lafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, Scherer SW, Lee C: **Detection of large-scale variation in the human genome.** *Nat Genet* 2004, **36**:949-51.
 F1000 Factor 6.7 *Must Read*
 Evaluated by Vivian Cheung 27 Aug 2004, Molly Przeworski 21 Sep 2004, Niklas Dahl 04 Oct 2004, Magnus Nordborg 14 Oct 2004
4. Koolen DA, Pfundt R, de Leeuw N, Hehir-Kwa JY, Nillesen WM, Neefs I, Scheltinga I, Sistermans E, Smeets D, Brunner HG, van Kessel AG, Veltman JA, de Vries BBA: **Genomic microarrays in mental retardation: a practical workflow for diagnostic applications.** *Hum Mutat* 2009, **30**:283-92.
5. Koolen DA, Vissers LELM, Pfundt R, de Leeuw N, Knight SJL, Regan R, Kooy RF, Reyniers E, Romano C, Fichera M, Schinzel A, Baumer A, Anderlid B-M, Schoumans J, Knoers NV, Geurts van Kessel A, Sistermans EA, Veltman J, Brunner HG, de Vries BBA: **A new chromosome 17q21.31 microdeletion syndrome associated with a common inversion polymorphism.** *Nat Genet* 2006, **38**:999-1001.
 F1000 Factor 6.0 *Must Read*
 Evaluated by Sue Malcolm 25 Sep 2006
6. Mefford HC, Sharp AJ, Baker C, Itsara A, Jiang Z, Buysse K, Huang S, Maloney VK, Crolla JA, Baralle D, Collins A, Mercer C, Norga K, de Ravel T, Devriendt K, Bongers EM, de Leeuw N, Reardon W, Gimelli S, Bena F, Hennekam RC, Male A, Gaunt L, Clayton-Smith J, Simonic I, Park SM, Mehta SG, Nik-Zainal S, Woods CG, Firth HV, et al.: **Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes.** *N Engl J Med* 2008, **359**:1685-99.
7. Szatmari P, Paterson AD, Zwaigenbaum L, Roberts W, Brian J, Liu XQ, Vincent JB, Skaug JL, Thompson AP, Senman L, Feuk L, Qian C, Bryson SE, Jones MB, Marshall CR, Scherer SW, Veland VJ, Bartlett C, Mangin LV, Goedken R, Segre A, Pericak-Vance MA, Cuccaro ML, Gilbert JR, Wright HH, Abramson RK, Betancur C, Bourgeron T, Gillberg C, Leboyer M, et al.: **Mapping autism risk loci using genetic linkage and chromosomal rearrangements.** *Nat Genet* 2007, **39**:19-28.
 F1000 Factor 3.0 *Recommended*
 Evaluated by Jens Rettig 04 Apr 2007
8. International Schizophrenia Consortium: **Rare chromosomal deletions and duplications increase risk of schizophrenia.** *Nature* 2008, **455**:237-41.
9. Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, Steinberg S, Fossdal R, Sigurdsson E, Sigmundsson T, Buizer-Voskamp JE, Hansen T, Jakobsen KD, Muglia P, Francks C, Matthews PM, Gylfason A, Halldorsson BV, Gudbjartsson D, Thorgeirsson TE, Sigurdsson A, Jonasdottir A, Jonasdottir A, Bjornsson A, Mattiasdottir S, Blondal T, Haraldsson M, Magnusdottir BB, Giegling I, Moller HJ, Hartmann A, et al.: **Large recurrent microdeletions associated with schizophrenia.** *Nature* 2008, **455**:232-6.
 F1000 Factor 6.0 *Must Read*
 Evaluated by Karoly Mirnics 08 Aug 2008
10. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM, Nord AS, Kusenda M, Malhotra D, Bhandari A, Stray SM, Rippey CF, Roccanova P, Makarov V, Lakshmi B, Findling RL, Sikich L, Stromberg T, Merriman B, Gogtay N, Butler P, Eckstrand K, Noory L, Gochman P, Long R, Chen Z, Davis S, Baker C, Eichler EE, Meltzer PS, et al.: **Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia.** *Science* 2008, **320**:539-43.
 F1000 Factor 8.4 *Exceptional*
 Evaluated by Jonathan Flint 08 Apr 2008, Gordon Fishell 09 Apr 2008, Michael Owen 09 Apr 2008, Guoping Feng 22 Apr 2008, Sue Malcolm 20 May 2008
11. Xu B, Roos JL, Levy S, van Rensburg EJ, Gogos JA, Karayiorgou M: **Strong association of de novo copy number mutations with sporadic schizophrenia.** *Nat Genet* 2008, **40**:880-5.
 F1000 Factor 3.0 *Recommended*
 Evaluated by Peter Scambler 14 Jul 2008
12. Sahoo T, Bacino CA, German JR, Shaw CA, Bird LM, Kimonis V, Anselm I, Waisbren S, Beaudet AL, Peters SU: **Identification of novel deletions of 15q11q13 in Angelman syndrome by array-CGH: molecular characterization and genotype-phenotype correlations.** *Eur J Hum Genet* 2007, **15**:943-9.
13. Cook EH Jr, Lindgren V, Leventhal BL, Courchesne R, Lincoln A, Shulman C, Lord C, Courchesne E: **Autism or atypical autism in maternally but not paternally derived proximal 15q duplication.** *Am J Hum Genet* 1997, **60**:928-34.
14. Sharp AJ, Mefford HC, Li K, Baker C, Skinner C, Stevenson RE, Schroer RJ, Novara F, De Gregori M, Ciccone R, Broome A, Casuga I, Wang Y, Xiao C, Barbacioru C, Gimelli G, Dalla Bernardina B, Torniero C, Giorda R, Regan R, Murday V, Mansour S, Fichera M, Castiglia L, Failla P, Ventura M, Jiang Z, Cooper GM, Knight SJL, Romano C, et al.: **A recurrent 15q13.3 microdeletion syndrome associated with mental retardation and seizures.** *Nat Genet* 2008, **40**:322-8.
15. van Bon BW, Mefford HC, Menten B, Koolen DA, Sharp AJ, Nillesen WM, Innis JW, de Ravel TJ, Mercer CL, Fichera M, Stewart H, Connell LE, Ounap K, Lachlan K, Castle B, Van der Aa N, van Ravenswaaij C, Nobrega MA, Serra-Juhé C, Simonic I, de Leeuw N, Pfundt R, Bongers EM, Baker C, Finnemore P, Huang S, Maloney VK, Crolla JA, van Kalmthout M, Elia M, et al.: **Further delineation of the 15q13 microdeletion and duplication syndromes: a clinical spectrum varying from non-pathogenic to a severe outcome.** *J Med Genet* 2009, **46**:511-23.
16. Pagnamenta AT, Wing K, Akha ES, Knight SJ, Bolte S, Schmotzger G, Duketis E, Poustka F, Klauck SM, Poustka A, Ragoussis J, Bailey AJ, Monaco AP: **A 15q13.3 microdeletion segregating with autism.** *Eur J Hum Genet* 2009, **17**:687-92.
17. Ghebranious N, Giampietro PF, Wesbrook FP, Rezkalla SH: **A novel microdeletion at 16p11.2 harbors candidate genes for aortic valve development, seizure disorder, and mild mental retardation.** *Am J Med Genet* 2007, **143A**:1462-71.
18. Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, Walsh T, Yamrom B, Yoon S, Krasnitz A, Kendall J, Leotta A, Pai D, Zhang R, Lee YH, Hicks J, Spence SJ, Lee AT, Puura K, Lehtimäki T, Ledbetter D, Gregersen PK, Bregman J, Sutcliffe JS, Jobanputra V, Chung W, Warburton D, King MC, Skuse D, Geschwind DH, Gilliam TC, et al.: **Strong association of de novo copy number mutations with autism.** *Science* 2007, **316**:445-9.
 F1000 Factor 6.9 *Must Read*
 Evaluated by Stephen Scherer 13 Apr 2007, James Fry 27 Apr 2007, Andrey Rzhetsky 02 May 2007, John Rubenstein 08 Jun 2007, Guoping Feng 25 Jul 2007
19. Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R, Saemundsen E, Stefansson H, Ferreira MAR, Green T, Platt OS, Ruderfer DM, Walsh CA, Altshuler D, Chakravarti A, Tanzi RE, Stefansson K, Santangelo SL, Gusella JF, Sklar P, Wu B-L, Daly MJ: **Association between microdeletion and microduplication at 16p11.2 and autism.** *N Engl J Med* 2008, **358**:667-75.
 F1000 Factor 3.2 *Recommended*
 Evaluated by Stephen Scherer 24 Jan 2008, Sue Malcolm 07 Feb 2008
20. Kumar RA, KaraMohamed S, Sudi J, Conrad DF, Brune C, Badner JA, Gilliam TC, Nowak NJ, Cook EH Jr, Dobyns WB, Christian SL: **Recurrent 16p11.2 microdeletions in autism.** *Hum Mol Genet* 2008, **17**:628-38.
21. Christian SL, Brune CW, Sudi J, Kumar RA, Liu S, Karamohamed S, Badner JA, Matsui S, Conroy J, McQuaid D, Gergel J, Hatchwell E, Gilliam TC, Gershon ES, Nowak NJ, Dobyns WB, Cook EH Jr: **Novel submicroscopic chromosomal abnormalities detected in autism spectrum disorder.** *Biol Psychiatry* 2008, **63**:1111-7.
22. de Vries BBA, Pfundt R, Leisink M, Koolen DA, Vissers LELM, Janssen IM, van Reijmersdal S, Nillesen WM, Huys EHLPG, de Leeuw N, Smeets D, Sistermans EA, Feuth T, van Ravenswaaij-Arts CMA, Geurts van Kessel A, Schoenmakers EFP, Brunner HG,

Veltman JA: **Diagnostic genome profiling in mental retardation.** *Am J Hum Genet* 2005, **77**:606-16.

F1000 Factor 3.0 Recommended

Evaluated by Stephen Scherer 19 Sep 2005

23. Kirov G, Grozeva D, Norton N, Ivanov D, Mantripragada KK, Holmans P, Craddock N, Owen MJ, O'Donovan MC: **Support for the involvement of large copy number variants in the pathogenesis of schizophrenia.** *Hum Mol Genet* 2009, **18**:1497-503.
24. Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skaug J, Shago M, Moessner R, Pinto D, Ren Y, Thiruvahindrapadam B, Fiebig A, Schreiber S, Friedman J, Ketelaars CEJ, Vos YJ, Ficicioglu C, Kirkpatrick S, Nicolson R, Sloman L, Summers A, Gibbons CA, Teebi A, Chitayat D, Weksberg R, Thompson A, Vardy C, Crosbie V, Luscombe S, Baatjes R, et al.: **Structural variation of chromosomes in autism spectrum disorder.** *Am J Hum Genet* 2008, **82**:477-88.
25. Emanuel BS: **Molecular mechanisms and diagnosis of chromosome 22q11.2 rearrangements.** *Dev Disabil Res Rev* 2008, **14**:11-8.
26. Chubykin AA, Liu X, Comoletti D, Tsigelny I, Taylor P, Sudhof TC: **Dissection of synapse induction by neuroligins: effect of a neuroligin mutation associated with autism.** *J Biol Chem* 2005, **280**:22365-74.
27. Feng J, Schroer R, Yan J, Song W, Yang C, Bockholt A, Cook EH Jr, Skinner C, Schwartz CE, Sommer SS: **High frequency of neurexin I beta signal peptide structural variants in patients with autism.** *Neurosci Lett* 2006, **409**:10-3.
28. Zahir FR, Baross A, Delaney AD, Eyedoux P, Fernandes ND, Pugh T, Marra MA, Friedman JM: **A patient with vertebral, cognitive and behavioural abnormalities and a de novo deletion of NRXN1 alpha.** *J Med Genet* 2008, **45**:239-43.
29. Friedman JM, Baross A, Delaney AD, Ally A, Arbour L, Asano J, Bailey DK, Barber S, Birch P, Brown-John M, Cao M, Chan S, Charest DL, Farnoud N, Fernandes N, Flibotte S, Go A, Gibson WT, Holt RA, Jones SJM, Kennedy GC, Krzywinski M, Langlois S, Li H, McGillivray BC, Nayar T, Pugh TJ, Rajcan-Separovic E, Schein JE, Schnerch A, et al.: **Oligonucleotide microarray analysis of genomic imbalance in children with mental retardation.** *Am J Hum Genet* 2006, **79**:500-13.
30. Strauss KA, Puffenberger EG, Huentelman MJ, Gottlieb S, Dobrin SE, Parod JM, Stephan DA, Morton DH: **Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2.** *N Engl J Med* 2006, **354**:1370-7.

F1000 Factor 3.0 Recommended

Evaluated by Angela Vincent 16 May 2006

31. Friedman JL, Vrijenhoek T, Markx S, Janssen IM, van der Vliet WA, Faas BH, Knoers NV, Cahn W, Kahn RS, Edelmann L, Davis KL, Silverman JM, Brunner HG, van Kessel AG, Wijmenga C, Ophoff RA, Veltman JA: **CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy.** *Mol Psychiatry* 2008, **13**:261-6.

F1000 Factor 3.0 Recommended

Evaluated by Michael Owen 27 Nov 2007

32. Sudhof TC: **Neuroligins and neurexins link synaptic function to cognitive disease.** *Nature* 2008, **455**:903-11.
33. McCarthy SE, Makarov V, Kirov G, Addington AM, McClellan J, Yoon S, Perkins DO, Dickel DE, Kusenda M, Krastoshevsky O, Krause V, Kumar RA, Grozeva D, Malhotra D, Walsh T, Zackai EH, Kaplan P, Ganesh J, Krantz ID, Spinner NB, Rocanova P, Bhandari A, Pavon K, Lakshmi B, Leotta A, Kendall J, Lee YH, Vacic V, Gary S, Lakoucheva LM, et al.: **Microduplications of 16p11.2 are associated with schizophrenia.** *Nat Genet* 2009, **41**:1223-7.

F1000 Factor 6.0 Must Read

Evaluated by Francine Benes 13 Nov 2009

34. Rujescu D, Ingason A, Cichon S, Pietilainen OP, Barnes MR, Touloupoulou T, Picchioni M, Vassos E, Ettinger U, Bramon E, Murray R, Ruggeri M, Tosato S, Bonetto C, Steinberg S, Sigurdsson E, Sigmundsson T, Petursson H, Gylfason A, Olason PI, Hardarsson G, Jonsdottir GA, Gustafsson O, Fossdal R, Giegling I, Moller HJ, Hartmann AM, Hoffmann P, Crombie C, Fraser G, et al.: **Disruption of the neurexin 1 gene is associated with schizophrenia.** *Hum Mol Genet* 2009, **18**:988-96.

F1000 Factor 6.0 Must Read

Evaluated by Francine Benes 28 Sep 2009

35. Fukumoto A, Hashimoto T, Ito H, Nishimura M, Tsuda Y, Miyazaki M, Mori K, Arisawa K, Kagami S: **Growth of head circumference in autistic infants during the first year of life.** *J Autism Dev Disord* 2008, **38**:411-8.
36. Girirajan S: **A recurrent 16p12.1 microdeletion modifies neurobehavioral phenotypes.** Paper presented at American Society of Human Genetics 59th Annual Meeting; 20-24 October 2009; Honolulu, HI, USA. Program 263.
37. Churchill GA, Airey DC, Allayee H, Angel JM, Attie AD, Beatty J, Beavis WD, Belknap JK, Bennett B, Berrettini W, Bleich A, Bogue M, Broman KW, Buck KJ, Buckler E, Burmeister M, Chesler EJ, Cheverud JM, Clapcote S, Cook MN, Cox RD, Crabbe JC, Crusio WE, Darvasi A, Deschepper CF, Doerge RW, Farber CR, Forejt J, Gaile D, Garlow SJ, et al.: **The Collaborative Cross, a community resource for the genetic analysis of complex traits.** *Nat Genet* 2004, **36**:1133-7.